Biomed Valley Discoveries (BVD) pipeline includes three assets: [1] a clinical stage best-in-class selective ERKi (ulixertinib) delivered orally as a mono therapy and in combination, [2] a clinical stage attenuated anaerobe bacteria (CNV-NT) delivered intratumorally for direct tumor killing and immune-stimulation, and [3] a preclinical stage antibody (TEM8) targeting the tumor microenvironment as an Antibody Drug Conjugate.  BVD is actively seeking licensing/collaboration of CNV-NT, and is scheduling discussions on ulixertinib and TEM8 for near-term transactions.